Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6068 participants.

Also called NCT01147250

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,068 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01147250
  • EudraCT 2009-012852-26
Other papers using this trial's data
  • Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome The New England journal of medicine, 2015-12-03 DOI, PubMed 26630143
  • Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration Journal of diabetes research, 2018 DOI, PubMed 30648112, PMC6311850 In the PMC Open Access subset under CC BY.
  • Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus Journal of the American Heart Association, 2017-05-29 DOI, PubMed 28554908, PMC5669146 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Guatemala, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway, Panama, Peru, Philippines, Poland, Portugal, Romania, Russia, Serbia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Türkiye, Ukraine, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01147250. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Acronym
ELIXA
Condition
Acute Coronary Syndrome
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Placebo
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01147250
Content hash
60c99e17a3b9d80ab11367e4df2b1d36d2657b5561819f602a268e4ec3c60624